Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?
04:12am, Monday, 19'th Jun 2023
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?
03:03am, Wednesday, 03'rd May 2023
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Volume Breakout Report Update: Buy Eton Pharmaceuticals
10:41pm, Monday, 16'th Jan 2023
A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late Ju
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Thursday, 17'th Nov 2022
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
11:17am, Tuesday, 11'th Oct 2022
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Immatics (IMTX) Stock Up 7% Today?
10:24am, Monday, 10'th Oct 2022
Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX ) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering.
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
10:08am, Wednesday, 20'th Jul 2022
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why you should consider buying and accumulating Immatics N.V.
06:28pm, Friday, 03'rd Jun 2022
Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
05:18pm, Friday, 03'rd Jun 2022
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates
09:47am, Thursday, 02'nd Jun 2022
Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb, Immatics expand CAR-T agreement
07:44am, Thursday, 02'nd Jun 2022
Shares of Immatics IMTX, +3.85% gained 9.0% in premarket trading on Thursday after the company said its deal with Bristol Myers Squibb Inc. BMY, -0.65% has expanded to include several off-the-shelf TC
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
09:47am, Friday, 13'th May 2022
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High?
11:17am, Friday, 15'th Apr 2022
The consensus price target hints at a 178.1% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
$84.78 Million in Sales Expected for Immatics (NASDAQ:IMTX) This Quarter
02:00am, Thursday, 23'rd Dec 2021 Transcript Daily
Wall Street brokerages predict that Immatics (NASDAQ:IMTX) will post sales of $84.78 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Immatics earnings, with the highest sales estimate coming in at $158.99 million and the lowest estimate coming in at $10.56 million. The business is scheduled to announce []
Bristol Myers returns to Immatics for a dual-targeting cancer drug
12:00pm, Tuesday, 14'th Dec 2021 BioPharma Dive
The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors.
